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OBJECTIVES: Diabetes is a chronic and potentially disabling disease that represents 
an important public health concern. Persons with diabetes are at increased risk of 
developing long-term complications and the treatment of diabetes complications is the 
most expensive form of diabetes care. Complications of diabetes also compound the 
economic cost of treating the condition which affects the individuals, families and 
society. This study aimed at calculating the cost of complications of type II diabetes in 
Pakistan. METHODS: Prevalence based Cost-of-Illness study was conducted in out-
patient clinics of Karachi, Pakistan in 2006. The study population was all the persons 
with type II diabetes who attended the clinics.. A pre-tested questionnaire was used to 
collect the data from 345 randomly selected persons with diabetes. RESULTS: Of the 
total sample 72% had at-least one co-morbidity/complication and 48% had more than 
1 co-morbidity/complications. From the complications, 55% had hypertension fol-
lowed by dyslipidemia (30%). The mean direct cost of those diabetics who had no 
complication (only 28% of the sample) was Rs. 1226 (∼US$20) compared to those who 
have one or more diabetes complication that is Rs 1779 (∼US$ 30) and this difference 
was statistically signiﬁcant (P < 0.005). About 40% of those who have one or more 
co-morbidity are not taking any medication for their health condition, which may 
further compound this cost in the future. CONCLUSIONS: It has been recognized that 
health care expenditures related to the complications of diabetes account for a substan-
tial proportion of the public health care budget. Reducing the risks of developing 
complications can improve the quality of life, increase life expectancy and reduce the 
overall cost to society. In this era of scarce resources and rising costs, it is critical to 
have an understanding of the economics of diabetes and its complications in order to 
develop and implement sound public health and prevention policies.
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OBJECTIVES: A number of studies have reported that patients with type 2 diabetes 
have higher annual mean expenditures than those without this condition. Additionally, 
the range of costs among these patients is quite large. Studies have also illustrated that 
certain acute events and co-morbidities drive excess mean costs. Whether these events 
and conditions affect cost in the same way across the distribution has not been studied. 
In order to more fully understand potential drivers of costs, we performed a descriptive 
analysis across quartiles of the cost distribution. METHODS: Data for this study come 
from a US health plan afﬁliated with i3 Innovus. We included members aged 18 or 
older that had evidence of type 2 diabetes over the period January 1, 2004 to Decem-
ber 31, 2006. An index date was deﬁned as the date of the earliest qualifying medical 
or pharmacy claim. Patients were required to have continuous enrollment two years 
prior to (baseline period) and 2 years following (follow-up period) the index date. 
Variables were created for the following categories: demographics characteristics, 
diagnoses, medications, procedures and clinical markers (e.g. lab values for HbA1C/
Lipids). Differences in potential cost drivers across the quartiles of the cost distribution 
were assessed. RESULTS: Mean annual cost for those in the highest quartile was 6X 
higher compared to those in the lowest quartile ($3,200 versus $19,700). Although 
there did not appear to be differences in HbA1c and lipid levels across the quartiles, 
meaningful differences were seen in many of the other variables analyzed. For 
example, “diseases of the heart” ranged from 17% in the lowest quartile to 42% in 
the highest quartile. CONCLUSIONS: The study illustrates that a quantile-based 
analytical approach may allow for a deeper understanding of the drivers of health 
care costs.
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OBJECTIVES: Study the medical cost of diabetes mellitus (DM) insurants and cost-
inﬂuence factors, analyze the utilization of pharmaceuticals and compare the settle-
ment pattern of medical insurance among various cities. METHODS: This retrospective 
study involved 1819 diabetes mellitus cases in 3 cities. A questionaire survey was 
conducted about their medical cost and health care utilization in 2007. The actual 
claim data were collected and analyzed. RESULTS: 1)The main inﬂuencing factors of 
patients’ medical cost include the severity of illness, complications, level of hospital 
and the hospital-owned city, and 2)Outpatient medical cost per head was 6337 yuan, 
which is 20% of the family income per head. Inpatient medical cost per head was 
9262 yuan, which is 71% of the annual income of the patient. The basic medical 
insurance(BMI) fund covered 63% and 61% of outpatient and inpatient cost, sepa-
rately. The cost of patients with complication is 1.4 times that without any complica-
tion. 3) The average inpatient cost occured in the ﬁrst level hospitals was 4176 yuan, 
and the cost in the second and third level hospitals was 1.47 and 2.74 times that in 
the ﬁrst level hospitals, separately. 4) Drug cost accounts for 73% of the outpatient 
medical expense, and the top 8 prescribing drugs account for 80% of all prescription. 
Drug cost accounts for 50% of the inpatient medical expense, and the cost of top 10 
money-consuming drugs account for 60% of total drug expense. It indicates that 
management of medical insurance should emphasize on monitoring of rational drug 
use. CONCLUSIONS: DM patients’ medical cost has a close connection with the level 
of hospital and the drug use. To encourage the patients to fully utilize community 
health service and health service providers to use drug rationally by adjusting medical 
insurance policy will help to control the medical cost.
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OBJECTIVES: Type 2 diabetes mellitus (T2DM) is increasing dramatically and associ-
ated with a substantial economic burden in the US. The objective of this retrospective 
database analysis was to describe overall health care costs and resource utilization of 
patients with T2DM using eligibility, medical and pharmacy claims data from a large, 
national US health care organization that manages commercially-insured and Medi-
care members. METHODS: Patients were ≥18 years with evidence of T2DM between 
January 2006 and December 31 2007 and continuous enrollment for 12 months before 
(pre-index period) and after (post-index period) the date of T2DM identiﬁcation. 
Overall post-index health care costs included medical (i.e., ambulatory, emergency 
services, inpatient, and other costs) and pharmacy costs, reﬂecting combined health 
plan and patient paid amounts. Post-index health care resource utilization included 
ambulatory visits (ofﬁce and outpatient), emergency department (ER) visits, and 
inpatient admissions. RESULTS: Among 14 million patients within the database, 
5.6% (n = 810,756) had evidence of T2DM. A total of 309,582 patients met the 
inclusion criteria. The mean age was 55.8 years and 45.2% were female. Mean overall 
health care costs (SD) were $11,644.41 ($27,904.19). Most of these were attributed 
to medical costs ($8,511.63 ($26,958.78)), of which the majority were ambulatory 
($4,282.98 ($12,799.05)). Mean pharmacy costs were $3,132.85 ($3,930.09). A total 
of 99.2% of patients (n = 307,531)) had > 1 ambulatory visits, while 27.5% (n = 
85,152) and 16.8% (n = 52,150) had ≥1 ER visits and inpatient stays, respectively. 
The mean number of ambulatory visits, ER visits and inpatient stays were 17.2 (16.3), 
0.8 (2.8) and 0.3 (0.7), respectively. Visits to specialists accounted for approximately 
two-thirds of all ambulatory visits. CONCLUSIONS: Patients with T2DM were costly 
and consumed a considerable amount of health care resources. The primary driver of 
overall health care costs and resource utilization were ambulatory visits, of which the 
majority were to specialists. Strategies to optimize appropriate specialist utilization 
may reduce overall costs in this patient population.
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OBJECTIVES: To quantify and compare annual resource use and costs over time 
among Swedish patients with type 2 diabetes ﬁrst treated with oral antidiabetic (OAD) 
medication alone and who subsequently initiated insulin treatment. METHODS: The 
study was based on data from the Real-Life Effectiveness and Care Patterns in Diabetes 
Management (RECAP-DM) study, a retrospective, population-based study on patients 
with type 2 diabetes identiﬁed in electronic patient records from 26 primary care 
centers in Uppsala county. Patients treated with OAD alone the year prior to insulin 
initiation in 2001–2003 were identiﬁed. Resource consumption was available from 
the patient records and the resource items included were visits to General practitioners 
(GP) or nurses at Primary care settings, visits to acute physician and visits at outpatient 
clinics and inpatient days. The annual costs were calculated by multiplying quantities 
of resource use by unit costs from a previous study and from the price list of Uppsala 
University Hospital. RESULTS: A total of 397 patients with type 2 diabetes were 
identiﬁed that initiated insulin treatment 2001–2003 after only receiving OAD. The 
annual resource use for diabetes nurse visits, visits to outpatient clinics and inpatient 
days increased signiﬁcantly for patients during the year after insulin initiation com-
pared to the year prior to insulin initiation when the patient received OAD alone. 
Even if annual resource use and costs for GP-visits decreased signiﬁcantly (p < 0.05) 
during the same period, total costs and the costs of diabetes nurse visits and inpatient 
days increased signiﬁcantly the year at and the year after insulin initiation compared 
to the year when the patient received OAD alone (costs for inpatient days p < 0.1). 
CONCLUSIONS: Patients initiating insulin treatment after receiving OAD alone 
consumes signiﬁcantly more annual resources. Annual mean costs also increase sig-
niﬁcantly, driven by the increased costs of inpatient days and diabetes nurse visits.
